Valuation
- Market cap
- 11,395,000
- Revenue TTM
- $1,180,000
- Net income TTM
- $-1,180,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -100.00%
- Debt to equity
- 0.40
Trading
- Volume
- 3,100
- Avg volume
- 17,066
- Day's range
- $2.31 – $2.37
- Shares out
- 4,849,000
- Stochastic %K
- 23%
- Beta
- 1.61
- Analysts
- Strong Sell
- Price target
- $22.00
Company profile
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic...
Show more
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 972 8 642 9100
- Website
- https://www.biolinerx.com
- Address
- Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, Israel
Latest news
No headlines yet.
